Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple immunotherapy cocktail shows promise against tough cancers

NCT ID NCT03744468

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now complete, and results will help guide future research on these combinations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tislelizumab, surzebiclimab, and alcestobart (three immunotherapy drugs that help the immune system attack cancer)

What this could lead to

If successful, this combination could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.

What could go wrong

This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to all patients. Side effects from immunotherapy can be serious, including immune-related inflammation in healthy organs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HNSCC FOR PHASE 2 DOSE EXPANSION LOCALLY ADVANCED OR METASTATIC SOLID TUMORS FOR PHASE 1, DOSE ESCALATION AND PHASE 2 SAFETY LEAD-IN LOCALLY ADVANCED OR METASTATIC SOLID TUMORS FOR PHASE 1,DOSE ESCALATION AND PHASE 2 SAFETY LEAD-IN, HNSCC, NSCLC AND RCC PARTICIPANTS FOR PHASE 2 NSCLC FOR PHASE 2 DOSE EXPANSION

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, 16499, South Korea

  • Asan Medical Center

    SongpaGu, Seoul Teugbyeolsi, 05505, South Korea

  • Box Hill Hospital

    Box Hill, Victoria, VIC 3128, Australia

  • Cabrini Research and Education Institute

    Malvern, Victoria, VIC 3144, Australia

  • Calvary North Adelaide Hospital

    North Adelaide, South Australia, SA 5006, Australia

  • Centre de Lutte Contre Le Cancer Francois Baclesse

    Caen, 14000, France

  • Centre de Lutte Contre Le Cancer Institut Bergonie

    Bordeaux, 33000, France

  • Chao Family Comprehensive Cancer Center

    Orange, California, 92868-3201, United States

  • Chungbuk National University Hospital

    SeowonGu CheongjuSi, Chungcheongbukdo, 28644, South Korea

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    Milan, 20133, Italy

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111-2434, United States

  • Gachon University Gil Medical Center

    NamdongGu, Incheon Gwang'Yeogsi, 21565, South Korea

  • Gold Coast University Hospital

    Southport, Queensland, QLD 4215, Australia

  • Hollywood Private Hospital

    Nedlands, Western Australia, WA 6009, Australia

  • Hospital Clinico San Carlos

    Madrid, 28040, Spain

  • Hospital Universitario Hm Madrid Sanchinarro

    Madrid, 28050, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, 41013, Spain

  • Institut Catala Doncologia

    Barcelona, 08908, Spain

  • Institut Curie Paris

    Paris, 75005, France

  • Irccs Azienda Ospedaliero Universitaria Bologna

    Bologna, 40138, Italy

  • Istituto Di Candiolo Irccs

    Torino, 10060, Italy

  • Linear Clinical Research

    Nedlands, Western Australia, WA 6009, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, SA 5112, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, VIC 3000, Australia

  • Schar Cancer Institute

    Fairfax, Virginia, 22031-4867, United States

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea

  • Sunshine Coast Hospital and Health Service

    Birtinya, Queensland, QLD 4575, Australia

  • Sydney Southwest Private Hospital

    Liverpool, New South Wales, NSW 2170, Australia

  • The Catholic University of Korea, Seoul St Marys Hospital

    SeochoGu, Seoul Teugbyeolsi, 06591, South Korea

  • The Catholic University of Korea, St Vincents Hospital

    PaldalGu SuwonSi, Gyeonggi-do, 16247, South Korea

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • Ulsan University Hospital

    Donggu, Ulsan Gwang'Yeogsi, 44033, South Korea

  • University of Chicago Medical Center

    Chicago, Illinois, 60637-1443, United States

  • University of Colorado Cancer Center

    Aurora, Colorado, 80045-2517, United States

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky, 40536-7001, United States

  • University of North Carolina At Chapel Hill

    Chapel Hill, North Carolina, 27514-4220, United States

  • University of Virginia

    Charlottesville, Virginia, 22908-0817, United States

  • Ut Health San Antonio Mays Cancer Center

    San Antonio, Texas, 78229-4427, United States

  • Weill Cornell Medical College Newyork Presbyterian Hospital

    New York, New York, 10065-4870, United States

  • Western Health Sunshine Hospital

    St Albans, Victoria, VIC 3021, Australia